Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD

Clinical trial NCT02603393 · COMPLETED

Trial details

NCT number

NCT02603393

Sponsor

Novartis Pharmaceuticals

Status

COMPLETED

Phase

Phase 4

Study type

INTERVENTIONAL

Start date

2015-11-20

Primary completion

2017-07-18

Enrollment

1053

View on ClinicalTrials.gov